Skip to main content
. 2020 Oct 28;12(11):1028. doi: 10.3390/pharmaceutics12111028

Figure 4.

Figure 4

(A) Analysis of nonmarketed formulations for cancer therapy that have entered phase III clinical trials classified by the type of therapy. (B) Analysis of nonmarketed formulations for cancer therapy that have entered phase III clinical trials classified by the type of formulation.